Iovance Biotherapeutics Inc (NASDAQ:IOVA) at last check was buoying at $12.43 on current market day with a rise of 2.39% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $12.14 and 5Y monthly beta was reading 0.594 with its price kept floating in the range of $12.13 and $12.5 on the day. Considering stock’s 52-week price range provides that IOVA hit a high price of $18.33 and saw its price falling to a low level of $3.76 during that period. Over a period of past 1-month, stock came adding 29.34% in its value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
With its current market valuation of $3.77 billion, Iovance Biotherapeutics Inc is set to declare its quarterly results on 2024-Nov-07. Analysts are in estimates of -0.3 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -1.29 for current year with estimates of that growing to -0.76 in next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of 53.81M. They suggested that in the process company could generate revenue of as low as 52.75M which could climb up to 54.85M to hit a high. The average estimate is representing an increase of 11,373.30% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of 162.76M in current fiscal year, which will be 13,588.80% more from revenue generated by the company last year.
In contrast, when we review IOVA stock’s current outlook then short term indicators are assigning it an average of 50% Buy, while medium term indicators are categorizing the stock at an average of 50% Buy. Long term indicators are suggesting an average of 50% Buy for it.
According to ratings assigned by 8 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 2 of them are recommending Iovance Biotherapeutics Inc (IOVA) as a Hold, while 6 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the IOVA stock which is currently positioned at 0. It further provides that stock’s current price level is 17.27% away from its 20-day simple moving average and is 21.74% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 70.40 while volatility remained at 5.63% over the past week which changes to 5.39% when measuring it over the past month. Beta is valued at 0.61, while measure of average true range or ATR is currently at 0.60. In predicting price targets of as low as $6 and as high as $40, analysts are in agreement on assigning the stock over the next 12 months average price target of $23. Stock’s current price level is 51.73% above from estimated low price target while it is -221.8% below the estimated high; and even if the IOVA’s share succeeded to reach the median price of $23, then the outlook of -85.04% could come to the excitement of the investors.
Having a second look at Iovance Biotherapeutics Inc (NASDAQ:IOVA) provides that stock’s average daily trading volume for 3 months was 5.82 million, while it jumped to 5730340 when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 256.14 million.
The percentage of outstanding shares held by the insiders is 18.58% while it is 68.74% for the institutional holders. The figures also indicate that as of 2024-10-15, number of stock’s short shares was 60.34 million which implies a short ratio of 14.23. This shows up a 2198.00 of Short Interest in company’s outstanding shares on the day. In October the standing of shares short improved as it was 60.29 million in the previous month. Addition of 52.89% by stock’s current price to its year-to-date value in today’s trading is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
